top
Please input keywords
OK
홍보센터
Contact us
KR
CN
EN
JP
회사소개
회사소개
회사 연혁
핵심인력
기업문화
사회적 책임
인재모집
합작연구개발
Collaborations
Antibody Assets
Project Integrum
Antibody discovery platforms
Pipeline
Clinical pipeline
Preclinical pipeline
RenMice
RenMab
RenLite
RenNano
동물/세포 모델
Humanized animal models
KO mouse models
Tool mice
Immunodeficient mice/rats
Cell lines
Aged mice
Disease mouse models
Pharmacology service
Therapeutic area
Types of services
Molecule type
Technology
유전자 편집
By species
By technologies
By strategies
Animal Breeding
Animal Cryopreservation
Animal Rederivation
Other Services
Microbial detection
Animal Breeding
Animal Cryopreservation
Animal Rederivation
IR
Stock Information
Financial Reports
Listing Documents
Announcements & Notices
Corporate Governance
Investor Calendar
Email Alert
IR Contact
Home
News events
자료 다운로드
포스터 다운로드
홍보센터
뉴스 및 각종 자료 열람
뉴스
공지사항
웨비나
논문게재실적
자료 다운로드
포스터 다운로드
제품정보 다운로드
2023
ESMO2023:Phase I open-label, dose escalation and expansion study of YH003, an anti-CD40 agonist monoclonal antibody in combination with Toripalimab in patients (pts) with advanced solid tumours
2023
AACR 2023: A First-In-Class Anti-HER2/TROP2 Bispecific Antibody-Drug Conjugate (YH012) Exhibits Potent Anti-Tumor Efficacy
2023
AACR 2023: YH013, a Novel Bispecific EGFR x MET Antibody-Drug Conjugate, Exhibits Potent Anti-Tumor Efficacy
2023
AACR 2023: BCG022: A Novel Bispecific Antibody-Drug Conjugate Targeting HER3 and MET
2023
AACR 2023: Discovery of BCG033, A Novel Anti-PTK7 x TROP2 Bispecific Antibody-Drug Conjugate with Promising Efficacy Against Triple-Negative Breast Cancer
2023
AACR 2023: RenNano® Mice: A Heavy-Chain-Only Antibody Platform for the Generation of Nanobody Therapeutics
2023
AACR 2023: Discovery of RenNano®-Derived Human Heavy-Chain-Only Antibodies That Cross the Blood-Brain-Barrier
2023
AACR 2023: Targeting Intracellular Tumor Antigens Using Fully Human TCR Mimic Antibodies Derived From HLA Transgenic RenMice
2023
AACR 2023: The RenMice HiTS (Hyperimmune Target Specific) Platform Facilitates Identification of Novel Therapeutic Antibodies for Challenging Targets
1
…
4
5
6
7
8
…
12
GO